Cancer

Print ISSN
0008-543X
Electronic ISSN
1097-0142
Impact factor
5.131
Publisher
wiley
URL
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-0142
Usage rank
26
Article count
37694
Free count
5957
Free percentage
0.158036
PDFs via platforms
Proquest, Rcgp, CSA, Ingenta, Wiley from 1948, Gale, and Ovid from 2005

  1. Etiologic role of human papillomavirus infection in bladder carcinoma.

    Cancer 117(10):2067 (2011) PMID 21523718

    The authors elucidated an etiologic role of human papillomavirus (HPV) infection in carcinoma of the bladder. One hundred seventeen of 224 patients with bladder carcinoma who were treated between 1997 and 2009 were enrolled in this study. The presence of HPV DNA was tested on frozen carcinoma ti...
  2. A phase 2 trial of dasatinib in advanced melanoma.

    Cancer 117(10):2202 (2011) PMID 21523734 PMCID PMC3116034

    Inhibiting src kinases (non-receptor tyrosine kinase signaling intermediates) reduces melanoma cell proliferation and invasion. Dasatinib inhibits c-kit, PDGFβR, and EPHA2 and src kinases c-src, c-Yes, Lck, and Fyn. A phase 2 trial of dasatinib in melanoma was conducted to assess response rate (...
  3. Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone.

    Cancer 117(10):2136 (2011) PMID 21523726

    In the era of novel agents such as lenalidomide and bortezomib, risk stratification by chromosomal abnormalities may enable a more rational selection of therapeutic approaches in patients with multiple myeloma (MM). The authors analyzed the prognostic value of deletion del(13q14), del(17p13), +1...
  4. Radiation-induced osteosarcomas of the calvarium and skull base.

    Cancer 117(10):2120 (2011) PMID 21523724

    Although a rare complication of ionizing radiation, radiation-induced osteosarcoma is now more frequently recognized as radiation therapy has become common and cancer survival has increased. To date, publications on radiation-induced osteosarcoma of the cranium are limited to a few small series ...
  5. Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia.

    Cancer 117(10):2163 (2011) PMID 21523729

    Early stage chronic lymphocytic leukemia is characterized by a highly variable course of disease. Because it is believed that regulatory T cells (T(regs) ) are potent suppressors of antitumor immunity, the authors hypothesized that increased T(regs) may favor disease progression. T(reg) levels (...
  6. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response.

    Cancer 117(10):2127 (2011) PMID 21523725

    In patients with chronic lymphocytic leukemia (CLL), treatment with lenalidomide induces a unique, previously uncharacterized, immune response called tumor flare reaction (TFR). The clinical significance of this reaction remains unknown. Forty-five patients with CLL who were treated with lenalid...
  7. Association of cyclophosphamide use with dental developmental defects and salivary gland dysfunction in recipients of childhood antineoplastic therapy.

    Cancer 117(10):2219 (2011) PMID 21523736

    The aim of this study was to examine the effect of antineoplastic therapy on dental development and saliva function in recipients of childhood antineoplastic therapy. Patients attending the long-term follow-up clinic at Children's Hospital at Westmead, NSW, Australia, were included if they had r...
  8. The cancer is over, now what?: Understanding risk, changing outcomes.

    Cancer 117(10 Suppl):2250 (2011) PMID 21523742

    About 26,000 adolescents and young adults ages 15 to 29 years are diagnosed with invasive cancer each year. Although >80% will survive beyond 5 years from their cancer diagnosis, many will develop serious morbidity or die prematurely secondary to health problems in part related to their cancer t...
  9. Adolescents and young adults with cancer: towards better outcomes in Canada. Preamble.

    Cancer 117(10 Suppl):2239 (2011) PMID 21523739

  10. Palliative care in adolescents and young adults with cancer.

    Cancer 117(10 Suppl):2323 (2011) PMID 21523753

    Adolescents and young adults (AYA) with advanced or terminal cancer have distinctive medical and psychosocial needs that may not have been adequately provided by either pediatric or adult palliative care services. A discussion group, as part of a larger workshop on AYA with cancer, was held in T...
  11. Treatment of cancer in adolescents and young adults: is affordability a concern?

    Cancer 117(10 Suppl):2258 (2011) PMID 21523743

    Progress in the treatment of cancers in young people has resulted in an increasing success rate in curing the different forms of malignant diseases. The mission of the CPAC/C(17) Task Force on Adolescents and Young Adults (AYA) with cancer is to ensure prompt, equitable access to the best care; ...
  12. Outcomes and metrics: measuring the impact of a comprehensive adolescent and young adult cancer program.

    Cancer 117(10 Suppl):2342 (2011) PMID 21523756

    Against a background of poorly coordinated provision of holistic care to the adolescent and young adult (AYA) cancer population, the Canadian National Task Force on Adolescent and Young Adult Oncology, which is supported by the Canadian Partnership Against Cancer and the C17 network, convened a ...
  13. Cancer genome variation in children, adolescents, and young adults.

    Cancer 117(10 Suppl):2262 (2011) PMID 21523744

    This mini-review describes the rapid changes in genome technologies that are leading to comprehensive views of genetic alterations in cancer, and presents high-level thoughts on ways to accelerate translation into clinical medicine. Issues that are more relevant to children, adolescents, and you...
  14. A phase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer.

    Cancer 117(10):2178 (2011) PMID 21523731

    The objective of this study was to investigate the efficacy of simvastatin in combination with irinotecan and cisplatin in chemotherapy-naive patients with extensive-disease small-cell lung cancer (ED-SCLC). In this phase 2 study, 61 patients received treatment with irinotecan (65 mg/m(2) ) and ...
  15. Lysyl oxidase: a lung adenocarcinoma biomarker of invasion and survival.

    Cancer 117(10):2186 (2011) PMID 21523732

    Lung adenocarcinoma invasion and metastasis arises from autocrine and paracrine signaling events between tumor epithelial cells and the stromal microenvironment that is mediated in part by transforming growth factor-β (TGF-β) signaling. The copper-dependent amine oxidase lysyl oxidase (LOX) play...
  16. A review of Canadian health care and cancer care systems.

    Cancer 117(10 Suppl):2241 (2011) PMID 21523740

    Canada is a westernized, market-economy nation with a publicly funded health care and cancer control system and has health indices reflective of a high-resource economy. Provision of health services is in accord with the Canada Health Act and is implemented through federal, provincial, and terri...
  17. Opportunities and challenges of establishing a nationwide strategy for adolescents and young adults in Canada with cancer: impressions from the Toronto workshop.

    Cancer 117(10 Suppl):2351 (2011) PMID 21523757

    Currently, there is priority to address the complex needs of the adolescent and young adult (AYA) cancer population. At a workshop in Toronto, the Canadian healthcare community brought together a broad range of stakeholders to discuss the opportunities and challenges of developing a nationwide s...
  18. Induction therapy and outcome in acute myeloid leukemia.

    Cancer 117(10):2236 (2011) PMID 21523737

  19. Genomic differences between estrogen receptor (ER)-positive and ER-negative human breast carcinoma identified by single nucleotide polymorphism array comparative genome hybridization analysis.

    Cancer 117(10):2024 (2011) PMID 21523713 PMCID PMC4521590

    Estrogen receptor (ER) remains one of the most important biomarkers for breast cancer subtyping and prognosis, and comparative genome hybridization has greatly contributed to the understanding of global genetic imbalance. The authors used single-nucleotide polymorphism (SNP) arrays to compare ov...
  20. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.

    Cancer 117(10):2050 (2011) PMID 21523716

    The purpose of this study was to compare 2 weekly docetaxel-based regimens as first-line treatments for advanced gastric cancer and to investigate the expression of secreted protein acidic and rich in cysteine (SPARC) and its abilities to predict treatment-related clinical outcomes. Patients wer...